Highlights the clinical management and risk stratification for sudden cardiac death in a patient with apical hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May guide individualized ICD decisions in apical HCM; leaves open validation of 5-year mortality risk models.
Hypertrophic cardiomyopathy (HCM) is a primary disease of the myocardium that is defined by the presence of regional (more frequent) or global myocardial hypertrophy, which usually results in functional cardiac impairment. We present a case of a 34-year-old man with apical HCM who was admitted to the cardiology department due to cardiac hypertrophy in the echocardiogram. The management of HCM patients is directed at heart failure treatment and decreasing left ventricular outflow tract or intraventricular gradient, if present. According to the patient’s calculated 5-year mortality risk, assessed using the HCM Risk-SCD Calculator, indications for implantation of an implantable cardioverter defibrillator were evaluated. JRCD 2017; 3 (5): 180–183
No takes yet. Share an insight, caveat, or question.
Dziewięcka et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: